Press Releases May 27, 2026 04:05 PM

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

BillionToOne to present at William Blair 46th Annual Growth Stock Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
BLLN

BillionToOne, Inc., a molecular diagnostics company specializing in DNA counting technology, announced its participation in the William Blair 46th Annual Growth Stock Conference, where management will present upcoming company developments.

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
BLLN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BillionToOne is showcased at a notable growth stock conference, highlighting its molecular diagnostics platform.
  • The company’s patented Quantitative Counting Templates™ (QCT™) technology enables accurate single-molecule DNA counting.
  • The event presentation is scheduled for June 2, 2026, with a live webcast available to investors.

MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the William Blair 46th Annual Growth Stock Conference.

Management will present from 12:40pm to 1:10pm Central Time on Tuesday, June 2, 2026.

A live and archived webcast will be available on the “Events & Presentations” page of BillionToOne’s investor relations website at https://investors.billiontoone.com/news-events/events-presentations.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.

Investor Contact
ir@billiontoone.com

Media Contact
billiontoone@moxiegrouppr.com


Risks

  • No new product launches or financial updates provided, limiting immediate impact on valuation.
  • Conference participation does not guarantee increased market interest or business growth.
  • Reliance on technological adoption in the molecular diagnostics sector which is competitive and subject to regulatory changes.

More from Press Releases

Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty Jun 8, 2026 Brookfield Real Assets Income Fund Inc. Announces Portfolio Management Team Change Jun 8, 2026 Real Messenger Corporation Announces Pricing of US$4.0 Million Public Offering Jun 8, 2026 SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK) Jun 8, 2026 One in Three Americans Delay Medical Care Due to Cost, HealthEquity Research Finds Jun 8, 2026